|
| Status |
Public on May 20, 2016 |
| Title |
AR and ERG ChIP-seq in presence or absence of PRMT5 |
| Organism |
Homo sapiens |
| Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
|
| Summary |
Replicates of ChIP seq data using AR and ERG antibodies from VCaP cell lines harboring inducible shRNA constructs for PRMT5 (3 independent, sh1, sh2, sh3) and 1 non targeting control (NTC), all sample stimulated with ligand, either DHT or R1881
|
| |
|
| Overall design |
AR ChIPseq in VCaP cells, 3 replicates each of DHT stimulated cells with one of 4 inducible shRNA constructs, sh1, sh2, sh3 targeting PRMT5 or NTC non targeting controls. Furthermore 2 AR ChIPseq in the same system stimulated with R1881 for targeting constructs sh1, sh2 and NTC. ERG ChIPseq 2 replicates DHT stimulated, each of sh1, sh2, sh3 constructs. Cells where induced (doxycyclin) for shRNA expression on day0, hormone starved on day3 and harvested on day5.
|
| |
|
| Contributor(s) |
Westerling T, Mounir Z, Pagliarini R, Brown M |
| Citation(s) |
27183006 |
| |
| Submission date |
Mar 11, 2016 |
| Last update date |
May 15, 2019 |
| Contact name |
Thomas Westerling |
| E-mail(s) |
thomas_westerling@dfci.harvard.edu
|
| Organization name |
Dana Farber Cancer institute
|
| Department |
Medical Oncology
|
| Lab |
Myles Brown
|
| Street address |
450 Brookline Ave
|
| City |
Boston |
| State/province |
MA |
| ZIP/Postal code |
02215 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
| Samples (26)
|
|
| Relations |
| BioProject |
PRJNA314989 |
| SRA |
SRP071668 |
Less...
More...